Summary
patients treated
Has anyone ever benefited from stem cell?
For the first time, umbilical cord blood cells were successfully used in 1988 in France. Several years later, in 2007, this method was also introduced by FamiCord Group in Poland. So far, umbilical cord blood stem cells have been transplanted over 40,000 times worldwide, saving peoples’ lives and health.
FamiCord Group enables their clients innovative treatment with stem cells. Check the full list of patients, suffered from diverse disorders, who benefited from it.
List of patients
| No. | Source | Source type | Diagnosis | Medical sector | Year of application | Therapy | Country | Age of the recipient |
|---|---|---|---|---|---|---|---|---|
| 2301 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2021 | Standard Therapy | Poland | 70 |
| 2302 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2021 | Standard Therapy | Poland | 8 |
| 2303 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2021 | Standard Therapy | Poland | 66 |
| 2304 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2021 | Standard Therapy | Poland | 26 |
| 2305 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2021 | Standard Therapy | Poland | 56 |
| 2306 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2021 | Standard Therapy | Poland | 63 |
| 2307 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2021 | Standard Therapy | Poland | 61 |
| 2308 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2021 | Standard Therapy | Poland | 70 |
| 2309 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2021 | Standard Therapy | Poland | 66 |
| 2310 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2021 | Standard Therapy | Germany | 48 |
| 2311 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2021 | Standard Therapy | Germany | 58 |
| 2312 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2021 | Standard Therapy | Germany | 59 |
| 2313 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 62 |
| 2314 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 63 |
| 2315 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 64 |
| 2316 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 66 |
| 2317 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 65 |
| 2318 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 56 |
| 2319 | Apheresis | Allogeneic | Myelofibrosis With Myeloid Metaplasia | Hematology | 2021 | Standard Therapy | Poland | 75 |
| 2320 | Apheresis | Allogeneic | Myelofibrosis With Myeloid Metaplasia | Hematology | 2021 | Standard Therapy | Poland | 65 |
| 2321 | Apheresis | Allogeneic | Myelofibrosis With Myeloid Metaplasia | Hematology | 2021 | Standard Therapy | Poland | 51 |
| 2322 | Apheresis | Allogeneic | Myelofibrosis With Myeloid Metaplasia | Hematology | 2021 | Standard Therapy | Poland | 63 |
| 2323 | Apheresis | Allogeneic | Myelofibrosis With Myeloid Metaplasia | Hematology | 2021 | Standard Therapy | Poland | 75 |
| 2324 | Apheresis | Allogeneic | Myelofibrosis With Myeloid Metaplasia | Hematology | 2021 | Standard Therapy | Poland | 64 |
| 2325 | Apheresis | Allogeneic | Myeloma Multiplex | Hematology | 2021 | Standard Therapy | Poland | 48 |
| 2326 | Apheresis | Allogeneic | Myeloma Multiplex | Hematology | 2021 | Standard Therapy | Poland | 53 |
| 2327 | Apheresis | Allogeneic | Myeloproliferative Neoplasms | Hematology | 2021 | Standard Therapy | Poland | 67 |
| 2328 | Apheresis | Allogeneic | Myeloproliferative Neoplasms | Hematology | 2021 | Standard Therapy | Poland | 58 |
| 2329 | Apheresis | Allogeneic | Myeloproliferative Neoplasms | Hematology | 2021 | Standard Therapy | Germany | 51 |
| 2330 | Apheresis | Allogeneic | No Data | Hematology | 2021 | Standard Therapy | Poland | 64 |
| 2331 | Apheresis | Allogeneic | No Data | Hematology | 2021 | Standard Therapy | Poland | 57 |
| 2332 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Poland | 30 |
| 2333 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Poland | 51 |
| 2334 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Poland | 58 |
| 2335 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Poland | 56 |
| 2336 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Poland | 58 |
| 2337 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Poland | 50 |
| 2338 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Poland | 53 |
| 2339 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Poland | 20 |
| 2340 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Poland | 64 |
| 2341 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Poland | 66 |
| 2342 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 62 |
| 2343 | Apheresis | Autologous | Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 61 |
| 2344 | Apheresis | Autologous | Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 49 |
| 2345 | Apheresis | Allogeneic | Non-Hodgkin-Lymphoma-Relapse | Hematology | 2021 | Standard Therapy | Germany | 62 |
| 2346 | Apheresis | Allogeneic | Osteomyelitis | Hematology | 2021 | Standard Therapy | Poland | 47 |
| 2347 | Apheresis | Allogeneic | Osteomyelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 69 |
| 2348 | Apheresis | Allogeneic | Osteomyelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 43 |
| 2349 | Apheresis | Autologous | Osteosclerotic Myeloma | Hematology | 2021 | Standard Therapy | Germany | 54 |
| 2350 | Apheresis | Allogeneic | Other Myelodysplastic Syndromes | Hematology | 2021 | Standard Therapy | Poland | 65 |
| 2351 | Apheresis | Allogeneic | Other Myelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 68 |
| 2352 | Apheresis | Allogeneic | Other Myelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 70 |
| 2353 | Apheresis | Allogeneic | Other Myelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 72 |
| 2354 | Apheresis | Allogeneic | Other Plasma Cell Disorder | Hematology | 2021 | Standard Therapy | Poland | 67 |
| 2355 | Apheresis | Allogeneic | Peripheral T-Cell Lymphoma | Hematology | 2021 | Standard Therapy | Poland | 45 |
| 2356 | Apheresis | Allogeneic | Philadelphia-Positive Acute Lymphoblastic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 61 |
| 2357 | Apheresis | Allogeneic | Polycythemia Vera | Hematology | 2021 | Standard Therapy | Poland | 65 |
| 2358 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 71 |
| 2359 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 66 |
| 2360 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 62 |
| 2361 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 53 |
| 2362 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 44 |
| 2363 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 54 |
| 2364 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 65 |
| 2365 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 65 |
| 2366 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 60 |
| 2367 | Apheresis | Allogeneic | Primary Myelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 66 |
| 2368 | Apheresis | Allogeneic | Primary Myelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 63 |
| 2369 | Apheresis | Allogeneic | Primary Myelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 62 |
| 2370 | Apheresis | Allogeneic | Primary Myelofibrosis | Hematology | 2021 | Standard Therapy | Poland | 64 |
| 2371 | Apheresis | Allogeneic | Prolymphocytic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 68 |
| 2372 | Apheresis | Allogeneic | Prolymphocytic Leukemia | Hematology | 2021 | Standard Therapy | Poland | 64 |
| 2373 | Apheresis | Allogeneic | Refractory Cytopenia | Hematology | 2021 | Standard Therapy | Poland | 6 |
| 2374 | Apheresis | Allogeneic | Secondary Acute Lymphoblastic Leukemia From Chronic Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Poland | 58 |
| 2375 | Apheresis | Allogeneic | Secondary Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Germany | 70 |
| 2376 | Apheresis | Allogeneic | Secondary Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Germany | 64 |
| 2377 | Apheresis | Allogeneic | Secondary Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Germany | 39 |
| 2378 | Apheresis | Allogeneic | Secondary Acute Myeloid Leukemia | Hematology | 2021 | Standard Therapy | Germany | 60 |
| 2379 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2021 | Standard Therapy | Poland | 35 |
| 2380 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2021 | Standard Therapy | Poland | 58 |
| 2381 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2021 | Standard Therapy | Poland | 41 |
| 2382 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2021 | Standard Therapy | Poland | 38 |
| 2383 | Apheresis | Allogeneic | Severe Combined Immunodeficiency | Hematology | 2021 | Standard Therapy | Poland | 1 |
| 2384 | Apheresis | Allogeneic | Severe Combined Immunodeficiency | Hematology | 2021 | Standard Therapy | Poland | 1 |
| 2385 | Apheresis | Allogeneic | T-Cell Lymphoblastic Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 26 |
| 2386 | Apheresis | Allogeneic | T-Cell Lymphoblastic Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 37 |
| 2387 | Apheresis | Autologous | T-Cell Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 54 |
| 2388 | Apheresis | Autologous | T-Cell Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 66 |
| 2389 | Apheresis | Autologous | T-Cell Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 66 |
| 2390 | Apheresis | Autologous | T-Cell Non-Hodgkin Lymphoma | Hematology | 2021 | Standard Therapy | Germany | 29 |
| 2391 | Apheresis | Allogeneic | T-Cell-Lymphoma | Hematology | 2021 | Standard Therapy | Poland | 45 |
| 2392 | Apheresis | Autologous | Testicular Cancer | Hematology | 2021 | Standard Therapy | Germany | 33 |
| 2393 | Apheresis | Allogeneic | Β – Thalassemia | Hematology | 2021 | Standard Therapy | Poland | 17 |
| 2394 | Adipose Tissue | Autologous | Gonarthrosis | Orthopedy | 2021 | Experimental Therapy | Poland | 51,1 |
| 2395 | Adipose Tissue | Autologous | Gonarthrosis | Orthopedy | 2021 | Experimental Therapy | Poland | 44,4 |
| 2396 | Adipose Tissue | Autologous | Gonarthrosis | Orthopedy | 2021 | Experimental Therapy | Poland | 35,8 |
| 2397 | Adipose Tissue | Autologous | Internal Damage To The Knee Joint | Orthopedy | 2021 | Experimental Therapy | Poland | 40.9 |
| 2398 | Adipose Tissue | Autologous | Soft Tissue Diseases Related To Use, Overload And Pressure | Orthopedy | 2021 | Experimental Therapy | Poland | 27,5 |
| 2399 | Placenta blood | Autologous | Cerebral Palsy | Neurology | 2020 | Experimental Therapy | Poland | 2,6 |
| 2400 | Cord Tissue | Allogeneic – Unrelated | Covid-19 | Pulmonology | 2020 | Experimental Therapy | Poland | 84,5 |